Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin

Show full item record



Permalink

http://hdl.handle.net/10138/325866

Citation

Lehtisalo , M , Keskitalo , J E , Tornio , A , Lapatto-Reiniluoto , O , Deng , F , Jaatinen , T , Viinamäki , J , Neuvonen , M , Backman , J T & Niemi , M 2020 , ' Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin ' , Clinical and translational science , vol. 13 , no. 6 , pp. 1236-1243 . https://doi.org/10.1111/cts.12809

Title: Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin
Author: Lehtisalo, Minna; Keskitalo, Jenni E.; Tornio, Aleksi; Lapatto-Reiniluoto, Outi; Deng, Feng; Jaatinen, Taina; Viinamäki, Jenni; Neuvonen, Mikko; Backman, Janne T.; Niemi, Mikko
Contributor: University of Helsinki, INDIVIDRUG - Individualized Drug Therapy
University of Helsinki, HUSLAB
University of Helsinki, HUSLAB
University of Helsinki, HUSLAB
University of Helsinki, INDIVIDRUG - Individualized Drug Therapy
University of Helsinki, HUSLAB
University of Helsinki, HUSLAB
University of Helsinki, HUSLAB
University of Helsinki, HUSLAB
Date: 2020-11
Language: eng
Number of pages: 8
Belongs to series: Clinical and translational science
ISSN: 1752-8054
URI: http://hdl.handle.net/10138/325866
Abstract: Xanthine oxidase inhibitors febuxostat and allopurinol are commonly used in the treatment of gout. Febuxostat inhibits the breast cancer resistance protein (BCRP) in vitro. Rosuvastatin is a BCRP substrate and genetic variability in BCRP markedly affects rosuvastatin pharmacokinetics. In this study, we investigated possible effects of febuxostat and allopurinol on rosuvastatin pharmacokinetics. In a randomized crossover study with 3 phases, 10 healthy volunteers ingested once daily placebo for 7 days, 300 mg allopurinol for 7 days, or placebo for 3 days, followed by 120 mg febuxostat for 4 days, and a single 10 mg dose of rosuvastatin on day 6. Febuxostat increased the peak plasma concentration and area under the plasma concentration-time curve of rosuvastatin 2.1-fold (90% confidence interval 1.8-2.6; P = 5 x 10(-5)) and 1.9-fold (1.5-2.5; P = 0.001), but had no effect on rosuvastatin half-life or renal clearance. Allopurinol, on the other hand, did not affect rosuvastatin pharmacokinetics. In vitro, febuxostat inhibited the ATP-dependent uptake of rosuvastatin into BCRP-overexpressing membrane vesicles with a half-maximal inhibitory concentration of 0.35 mu M, whereas allopurinol showed no inhibition with concentrations up to 200 mu M. Taken together, the results suggest that febuxostat increases rosuvastatin exposure by inhibiting its BCRP-mediated efflux in the small intestine. Febuxostat may, therefore, serve as a useful index inhibitor of BCRP in drug-drug interaction studies in humans. Moreover, concomitant use of febuxostat may increase the exposure to BCRP substrate drugs and, thus, the risk of dose-dependent adverse effects.
Subject: DRUG-DRUG INTERACTION
HEPATIC-UPTAKE
ABCG2 BCRP
PHARMACOKINETICS
TRANSPORTER
GOUT
ELTROMBOPAG
OATP1B1
RISK
ATORVASTATIN
3111 Biomedicine
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
cts.12809.pdf 611.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record